acalabrutinib in mcl
play

ACALABRUTINIB IN MCL Simon Rule Professor of Clinical Haematology - PowerPoint PPT Presentation

Feb 28, 2024 •618 likes •878 views

ACALABRUTINIB IN MCL Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth UK BRUTON S TYROSINE KINASE (BTK): A CRITICAL KINASE FOR LYMPHOMA CELL SURVIVAL AND

  1. ACALABRUTINIB IN MCL Simon Rule Professor of Clinical Haematology Consultant Haematologist Derriford Hospital and Peninsula Medical School Plymouth UK

  2. BRUTON’ S TYROSINE KINASE (BTK): A CRITICAL KINASE FOR LYMPHOMA CELL SURVIVAL AND PROLIFERATION • Bruton’s tyrosine kinase (BTK) is an essential element of the BCR signaling pathway (Niiro, NRI 2002) • Inhibitors of BTK block BCR signaling and induce apoptosis • BTK also acts downstream of certain chemokine receptors impacting integrin molecules that help in promoting egression from the lymph node environment EHA 2013, PCYC-1104 Rule et al. 2

  3. Ibrutinib: A potent BTK inhibitor • Ibrutinib (PCI-32765) forms a bond with cysteine-481 in BTK • Highly potent BTK inhibition at IC 50 = 0.5 nM • High degree of specificity for hematopoietic cells • Orally administered once daily dosing until PD or no longer tolerated by patient Durable Btk inhibition, despite rapid drug EHA 2013, PCYC-1104 Rule et al. 3 elimination Plasma concentrations of ibrutinib vs. BTK occupancy 100% 70 90% 60 Btk Active-Site Occupancy 80% Plasma Concentration 50 70% Plasma Conc (ng/mL) 60% % Active-Site Occupancy 40 50% 30 40% Patients dosed at 2.5 mg/kg/day 30% 20 20% 10 10% 0 0% 0 4 8 12 16 20 24 28 Time Postdose (h) Advani et al. J Clin Oncol 28:15s, 2010 (suppl; abstr 8012)

  4. NEXT GENERATION BTKI’S ONO 4059 ACP 196 M 7583

  5. ACALABRUTINIB: A HIGHLY SELECTIVE, POTENT BRUTON TYROSINE KINASE (BTK) INHIBITOR • Acalabrutinib was developed to increase the degree of BTK inhibition ◦ Very low binding to interleukin-2 inducible T-cell kinase (ITK), TEC protein tyrosine kinase (TEC), and epidermal growth factor receptor (EGFR) • Acalabrutinib selectively binds with a short half-life allowing twice-daily dosing and near total BTK inhibition ◦ Potentially reducing drug resistance • Acalabrutinib appears to improve substantially on the specificity of first generation BTK inhibitors Byrd JC, Harrington B, O’Brien S, et al. N Engl J Med 2016;374:323-32. Supplement. DOI: 10.1056/NEJMoa1509981. 6 Wilson, WH. N Engl J Med 2016; 374:386-388.

  6. Awan F, et al. ASH 2016 ACALABRUTINIB (ACP-196) • Acalabrutinib is a highly selective, potent BTK inhibitor • Minimal off-target effects on TEC, EGFR, or ITK signaling in vitro Kinase Selectivity Profiling at 1  mol/L 1 Kinase Inhibition IC 50 (nmol/L) 1 Kinase Acalabrutinib Ibrutinib Ibrutinib Acalabrutinib 5.1 1.5 BTK TEC 93 7.0 BMX 46 0.8 368 2.0 TXK ERBB2 ~1000 6.4 EGFR >1000 5.3 ITK >1000 4.9 JAK3 >1000 32 Larger red circles represent stronger inhibition BLK >1000 0.1 1 Covey AACR 2015. Abstract 2596. 6

  7. Byrd JC et al. N Engl J Med . 2016;374(4):323-332. PHARMACOKINETICS/PHARMACODYNAMICS 1-hour half-life; rapid oral absorption; complete BTK occupancy Plasma Concentration of Acalabrutinib Over Time BTK Occupancy, All Cohorts 10 4 100 mg QD 175 mg QD 250 mg QD BTK Occupancy (%) 400 mg QD 10 3 Mean Concentration 100 mg BID (ng/mL) 10 2 10 1 1 0 1 2 3 4 5 6 Cohort Hour After Administration 7

  8. Byrd JC et al. N Engl J Med . 2016;374(4):323-332. ACALABRUTINIB TWICE-DAILY DOSING (COMPLETE AND CONTINUOUS BTK COVERAGE) BTK Occupancy, 100-mg, Twice-Daily Cohort 100 BTK Occupancy (%) 90 N=28 N=26 N=27 N=27 N=28 N=19 80 50 97% 95% 97% 99% 97% 99% Median 97% 95% 97% 99% 97% 99% 0 N=28 N=26 N=27 N=27 N=28 N=19 Time of Assessment 8

  9. ACE-LY-004: AN OPEN-LABEL, GLOBAL PHASE 2 STUDY OF ACP-196 IN SUBJECTS WITH MANTLE CELL LYMPHOMA (MCL) • ACP-196 is an investigational oral Bruton tyrosine kinase (Btk) inhibitor • ACP-196 is a second-generation, potent, selective, covalent inhibitor of Btk bortezomib ACP-196 exposed 100mg BID b R/R MCL Screening N= 117 a single-arm study bortezomib ACP-196 naïve 100mg BID b a Planned sample size, anticipated completion Q1’2016 b Subjects will be followed every 28 days or until progression of disease or start of another anti-cancer treatment for at least 1 year

  10. CLINICAL EFFICACY IN MCL

  11. MR CT Pre ACP CT C2D28

  12. MR PET Pre PET C2D28

  13. 91 YEAR OLD MALE WITH MANTLE CELL LYMPHOMA • Presents with B-symptoms, leukocytosis and bulky lymphadenopathy – Jan 2015 • Commenced Rituximab-chlorambucil • Fails to respond after 2 cycles with significant cytopenias. • Commenced ACP- 196 (June ‘15) • Partial remission with leukocytosis within 1 month – excellent clinical response. • Significant bruising – aspirin stopped • PET negative PR on imaging with residual marrow involvement at 9 months. • Very good partial remission at 12 months

  14. SIDE EFFECTS

  15. The Bruton Tyrosine Kinase Inhibitor ACP-196 / ASH 2015: Abstract #831 PLATELET AGGREGATION (R/R PATIENTS WITH CLL) ACP-196 does not inhibit platelet mediated thrombosis Healthy Adult PBMCs (N=5) 100mg BID ACP-196 (N=3) 420mg QD ibrutinib (N=5) In vivo murine thrombosis model. Chen, et al. Blood. 2014. 15

  17. BLEEDING WITH PROCEDURES

  18. Acalabrutinib Monotherapy in Patients With Richter Transformation From the Phase 1/2 ACE-CL-001 Clinical Study Peter Hillmen, 1 Anna Schuh, 2 Toby A. Eyre, 3 John M. Pagel, 4 Jennifer R. Brown, 5 Paolo Ghia, 6 John N. Allan, 7 William Wierda, 8 Ahmed Hamdy, 9 Raquel Izumi, 9 Priti Patel, 9 Min Hui Wang, 9 John C. Byrd 10 1 St. James’s University Hospital, Leeds, UK; 2 Department of Oncology, University of Oxford, Oxford, UK; 3 Department of Haematology, Churchill Hospital Cancer Centre, Oxford, UK; 4 Swedish Medical Center, Seattle, WA; 5 Dana-Farber Cancer Institute, Boston, MA; 6 Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milano, Italy; 7 Weill Cornell Medical College, New York Presbyterian Hospital, New York, NY; 8 The University of Texas MD Anderson Cancer Center, Houston, TX; 9 Acerta Pharma, Redwood City, CA; 10 The Ohio State University Comprehensive Cancer Center, Columbus, OH | Strictly Confidential 18

  19. Hillmen P, et al. ASH 2016 MOST COMMON AES (≥15%) FOR ALL PATIENTS (N = 29) All AEs Treatment-Related AEs Grade ≥3 Grade ≥3 AE, n (%) All Grades All Grades Headache 12 (41) 0 10 (35) 0 Diarrhea 10 (35) 0 6 (21) 0 Anemia 9 (31) 4 (14) 4 (14) 1 (3) Fatigue 7 (24) 2 (7) 0 0 Arthralgia 5 (17) 1 (3) 2 (7) 0 Back pain 5 (17) 3 (10) 0 0 Multiple occurrences of the same event for a given patient were counted once for each Preferred Term. • Grade ≥3 AEs occurred in 18 patients (62%). • 2 patients experienced grade 5 AEs: cerebellar abscess and sepsis. – These events were deemed unrelated to study drug by the investigator. 19 | Strictly Confidential

  20. Hillmen P, et al. ASH 2016 SAFETY • Grade ≥3 AEs that occurred in ≥2 patients were anemia and neutropenia (n = 4; 14% each), hypercalcemia, back pain (n = 3; 10% each), fatigue, asthenia, and acute kidney injury (n = 2; 7% each). • SAEs occurred in 16 patients (55%). – SAEs in ≥2 patients were hypercalcemia (n = 3; 10%), fatigue and acute kidney injury (n = 2; 7% each). • No patients discontinued because of AEs. 20 | Strictly Confidential

  21. Hillmen P, et al. ASH 2016 TIME ON TREATMENT Median time on treatment: 3.4 CR CR months (range, 1.7-12.0 months). F PR PR SD SD PD PD Unknown Unknown Discontinued P due to PD Ongoing Ongoing P / / alloSCT / / alloSCT / / / / P 0 2 4 6 8 10 12 14 Time on Treatment (months) Time on Treatment (months) F, FL; P, PLL. 21 | Strictly Confidential

  22. The Bruton Tyrosine Kinase Inhibitor ACP-196 / ASH 2015: Abstract #831 ADVERSE EVENTS (MEDIAN 14.3 MONTHS OF FOLLOW-UP) Reported in ≥5% patients Adverse Events (Treatment-Related), n (%) Grade 1-2 Grade 3 N=61 – Headache 12 (20) 12 (20) – Increased tendency to bruise 7 (12) 7 (12) – Petechiae 7 (12) 7 (12) – Diarrhea 6 (10) 6 (10) – Ecchymosis 5 (8) 5 (8) Reported in ≥20% patients Adverse Events (Treatment-Emergent), n (%) Grade 1-2 Grade 3 N=61 – Headache 26 (43) 26 (43) Diarrhea 23 (38) 1 (2) 24 (39) Increased weight 15 (25) 1 (2) 16 (26) Pyrexia 12 (20) 2 (3) 14 (23) – Upper respiratory tract infection 14 (23) 14 (23) Fatigue 11 (18) 2 (3) 13 (21) – Peripheral edema 13 (21) 13 (21) 22 01Oct2015; R/R CLL patients.

  23. The Bruton Tyrosine Kinase Inhibitor ACP-196 / ASH 2015: Abstract #831 SERIOUS ADVERSE EVENTS (MEDIAN 14.3 MONTHS OF FOLLOW-UP) Reported in all patients Serious Adverse Events (Treatment-Related), n (%) Grade N=61 Febrile neutropenia 4 1 (2) Reported in ≥2 patients Serious Adverse Events (Treatment-Emergent), n (%) Grade N=61 3-4-5 † Pneumonia 6 (10) Autoimmune hemolytic anemia 3 2 (3) Pyrexia 2-3 2 (3) 01Oct2015; R/R CLL patients. † 1 fatal pneumonia, unrelated. No atrial fibrillation or major bleeding events 23

  24. CONCLUSION ACP-196 is a second-generation, selective Btk inhibitor with favorable biochemical and pharmacokinetic properties. ACP-196 has a promising safety profile In CLL patients; no episodes of atrial fibrillation or major bleeding observed at this time. Head to head trial v ibrutinib on-going in CLL Early onset treatment-related lymphocytosis was not as significant or persistent as reported with other BCR antagonists. In MCL data awaited!

More recommend